Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Apr 15;83(8):1112-26.
doi: 10.1016/j.bcp.2012.01.030. Epub 2012 Feb 4.

Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters

Yakun Chen  1 , Yong Tang, Changxiong Guo, Jiuhui Wang, Debasish Boral, Daotai Nie
Affiliations
Review

Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters

Yakun Chen et al. Biochem Pharmacol. .

Abstract

Chemotherapy is one of the three most common treatment modalities for cancer. However, its efficacy is limited by multidrug resistant cancer cells. Drug metabolizing enzymes (DMEs) and efflux transporters promote the metabolism, elimination, and detoxification of chemotherapeutic agents. Consequently, elevated levels of DMEs and efflux transporters reduce the therapeutic effectiveness of chemotherapeutics and, often, lead to treatment failure. Nuclear receptors, especially pregnane X receptor (PXR, NR1I2) and constitutive androstane activated receptor (CAR, NR1I3), are increasingly recognized for their role in xenobiotic metabolism and clearance as well as their role in the development of multidrug resistance (MDR) during chemotherapy. Promiscuous xenobiotic receptors, including PXR and CAR, govern the inducible expressions of a broad spectrum of target genes that encode phase I DMEs, phase II DMEs, and efflux transporters. Recent studies conducted by a number of groups, including ours, have revealed that PXR and CAR play pivotal roles in the development of MDR in various human carcinomas, including prostate, colon, ovarian, and esophageal squamous cell carcinomas. Accordingly, PXR/CAR expression levels and/or activation statuses may predict prognosis and identify the risk of drug resistance in patients subjected to chemotherapy. Further, PXR/CAR antagonists, when used in combination with existing chemotherapeutics that activate PXR/CAR, are feasible and promising options that could be utilized to overcome or, at least, attenuate MDR in cancer cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Regulation of Phase I & II DMEs and drug transporter genes by nuclear receptors PXR and CAR. After ligand binding, cytoplasimc fractions of PXR translocates to the nucleus while CAR dissociates from its complex, comprised of tetratricopeptide repeat (TTR), cytoplasmic CAR retention protein (CCRP), 90-kDa heat shock protein (hsp90) and PPP1R16A, and translocates from the cytoplasm to the nucleus. Subsequently, both PXR and CAR form heterodimers with RXR and bind to their respective response elements to stimulate transcription of phase I & II DMEs and drug transporters.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30. - PubMed
    1. Bates SE, Regis JI, Robey RW, Zhan Z, Scala S, Meadows BJ. Chemoresistance in the clinic: overview 1994. Bull Cancer. 1994;81 (Suppl 2):55s–61s. - PubMed
    1. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res. 2002;8:885–92. - PubMed
    1. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005;23:3948–56. - PubMed
    1. Mansouri A, Henle KJ, Nagle WA. Tumor drug-resistance: a challenge to therapists and biologists. Am J Med Sci. 1994;307:438–44. - PubMed

MeSH terms